Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-01-01 Legal Proceedings Report
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
涉及诉讼进展公告
Legal Proceedings Report Classification · 100% confidence The document is a public announcement from a company regarding the progress of a legal lawsuit involving the company. It details the background of the case, recent court rulings, and the potential impact on the company's profits. There is no financial data, no report attached or referenced as being published, and no mention of annual or interim reports. The content focuses solely on legal proceedings and updates related to a lawsuit. Therefore, this document fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a certification or a report publication announcement, so it is not RNS or RPA.
2024-01-01 Chinese
北京市环球（深圳）律师事务所关于云南生物谷药业股份有限公司 2023 年第四次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter from a law firm regarding the legality and procedural compliance of the 2023 fourth extraordinary general meeting of shareholders of Yunnan Shengwu Valley Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or performance data but focuses on the legal validation of the shareholders' meeting process and outcomes. This type of document is typically associated with the Declaration of Voting Results & Voting Rights Announcements category, as it officially reports the voting results and confirms their legality and validity.
2023-12-20 Chinese
2023年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 fourth extraordinary general meeting of shareholders of Yunnan Biological Valley Pharmaceutical Co., Ltd. It includes information about the meeting date, attendance, agenda items, voting results, and legal opinions. The content focuses on shareholder meeting decisions such as share cancellation, amendments to the company charter, and purchase of directors and officers liability insurance. It is not a full annual or interim report, nor a financial statement or earnings release. It is not a proxy solicitation or voting results announcement alone, but a formal announcement of the meeting resolutions. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters, but it contains detailed voting results and resolutions, not just a brief notice or report publication announcement. Therefore, the best classification is DVA with high confidence.
2023-12-20 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "公司章程" which translates to "Company Articles of Association" or "Company Bylaws." It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and governance rules. It references relevant laws and regulations such as the Company Law of the People's Republic of China and securities regulations. The content is a comprehensive governance document that sets out the internal rules and procedures for the company and its shareholders. It is not a financial report, earnings release, or announcement of voting results. It is not a proxy statement or remuneration report. It is a governance document detailing the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the actual governance document, not an announcement or summary.
2023-12-20 Chinese
关于注销部分已回购股份通知债权人的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company regarding the cancellation of repurchased shares and notification to creditors. It details the board and shareholder meetings approving the cancellation, the number of shares to be cancelled, the reduction in total shares and registered capital, and instructions for creditors to claim debts or request guarantees within a specified period. The content focuses on share cancellation and creditor notification rather than financial results, management changes, or regulatory filings. This fits the category of a Transaction in Own Shares (POS) as it involves the company's repurchased shares being cancelled, affecting the capital structure.
2023-12-20 Chinese
关于股东被拍卖的股份完成过户的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the completion of share transfer following a judicial auction of shares held by a shareholder. It details the auction process, the change in shareholding, and the impact on the company. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a change in share ownership due to a legal proceeding, but it is not a major shareholding notification (MRQ) since it relates to a judicial auction and transfer completion. It is not a full financial report or earnings release. The document is best classified as a Regulatory Filing (RNS) because it is a formal disclosure of a share transfer event due to judicial auction, which does not fit other specific categories.
2023-12-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.